Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
At the end of 2022, adagrasib received its first FDA approval for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer. Research is ongoing into adagrasib, a KRAS G12 inhibitor, for other tumors.
In today’s episode, we are joined by Jun Gong, MD, associate professor of medicine and the medical director of colorectal cancer in the Division of Medical Oncology at Cedars-Sinai Medical Center. During this interview, he discusses the mechanism of adagrasib, what other diseases it is being studied in, the latest data on adagrasib in colorectal cancer, and the importance of conducting genomic testing.
Listen above or through one of these podcast services:
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents
May 2nd 2024Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen